28-06-2022
Kedrion Biopharma Recognized for Innovation in Treating Rare Disease
Read all
RYPLAZIM® is the first FDA Approved Treatment for Plasminogen Deficiency Type 1
17-02-2022
Kedrion Biopharma Extends Contract Manufacturing Agreement (CMA) for GAMMAKED in the US, Ensuring Availability to Patients
Read all
Kedrion Biopharma will continue to market and distribute GAMMAKED in the U.S. through end of 2025
02-12-2021
Kedrion Biopharma to commercialize RYPLAZIM® in U.S
Read all
RYPLAZIM® (plasminogen, human-tvmh) will address needs in patients with ultra-rare condition Plasminogen Deficiency Type 1